2-(6-Chloro-2-Methylpyrimidin-4-Ylamino)-N-(2-Chloro-6-Methylphenyl)Thiazole-5-Carboxamide

Positioned as an analytical reference standard for the impurity control strategy of the tyrosine kinase inhibitor dasatinib monohydrate, 2-(6-Chloro-2-Methylpyrimidin-4-Ylamino)-N-(2-Chloro-6-Methylphenyl)Thiazole-5-Carboxamide corresponds to Impurity D as defined in the European Pharmacopoeia monograph for dasatinib (Ph. Eur. 2839). This compound, with the molecular formula C₁₆H₁₃Cl₂N₅OS and a relative molecular mass of 394.28 g·mol⁻¹, is the 4-(2-hydroxyethyl)piperazin-1-yl-deficient chloro analogue of the parent drug. Its primary commercial availability is as a certified reference material (CRM) with a declared purity of not less than 98.0 area% by HPLC (UV detection at 254 nm), supported by a comprehensive certificate of analysis that includes identity confirmation via ¹H NMR, ¹³C NMR, HRMS, and IR spectroscopy. Specification sheets for research-grade lots typically list an assay of ≥97% (qNMR or HPLC versus an external standard), water content by Karl Fischer coulometry below 0.5%, residual solvents compliant with ICH Q3C Option 2 limits, and a melting point (DSC onset, 10 K·min⁻¹) falling in the interval 198–202 °C, though polymorphism may shift the endotherm window.

When does reliance on this impurity standard become critical for regulatory filing?

During process validation and forced-degradation studies of dasatinib drug substance, the chloro impurity can arise from incomplete displacement of the 6-chloro substituent by 2-(piperazin-1-yl)ethanol under sub-optimal amination conditions. Its toxicological qualification threshold, guided by ICH M7 (R2) for mutagenic impurities, demands that the level in the finished drug substance remains below the acceptable intake of 15 µg·day⁻¹ unless bacterial mutagencity (Ames) data warrant a higher limit. Consequently, any commercial dasatinib active pharmaceutical ingredient (API) batch must be tested using a validated HPLC or UHPLC method that resolves Impurity D from the main peak and from other process-related impurities such as the des-hydroxyethyl piperazine analogue (Impurity C) and the N-oxide degradation product. The method commonly employs a C18 column (150 × 4.6 mm, 3.5 µm) with a mobile phase composed of ammonium acetate buffer at pH 4.5 and acetonitrile in a gradient program from 20% to 80% organic over 30 minutes, operated at a flow rate of 0.8 mL·min⁻¹. System suitability requires resolution between Impurity D and dasatinib ≥ 2.0, with relative retention time (RRT) of Impurity D typically observed at 1.45 relative to dasatinib. The availability of a batch-specific, quantitative reference standard with an assigned purity value traceable to a compendial standard allows quality control laboratories to calibrate the response factor and to conduct spike-and-recovery experiments in the range of the reporting threshold (0.05% w/w). Without this standard, accurate quantitation of Impurity D at the 0.10% specification limit—set by many marketing authorization holders based on process capability—cannot be reliably demonstrated.

Physicochemical characterisation and batch-to-batch variability in research-grade material

Beyond its compendial role, the compound is supplied as a yellow to off-white crystalline powder with characteristic X-ray powder diffraction peaks (Cu Kα radiation) at 2θ values of 9.8°, 14.3°, and 23.5° ± 0.2°. The solubility profile, measured at 25 °C, demonstrates poor aqueous solubility (<0.01 mg·mL⁻¹ in pH 6.8 phosphate buffer) and enhanced solubility in dimethyl sulfoxide (>25 mg·mL⁻¹) and dimethylformamide (> 15 mg·mL⁻¹). Such solubility characteristics are critical when preparing stock solutions for analytical method validation, as precipitation in aqueous mobile-phase diluents can lead to peak area variability exceeding 5% RSD. Manufacturers of research-grade material typically specify a retention time consistency criterion on their certificate of analysis—the observed retention time in a standardized HPLC method may not deviate more than ±0.1 min from the reference chromatogram provided. Batch-to-batch variability in purity profiles is negligible when the compound is produced via a high-yielding nucleophilic aromatic substitution of 4,6-dichloro-2-methylpyrimidine with 2-aminothiazole-5-carboxylic acid, followed by amide coupling with 2-chloro-6-methylaniline. Non-GMP lots often contain identifiable process impurities at levels below 0.5 area%, chiefly the regioisomer resulting from substitution at the 2-position of the pyrimidine ring and the bis-chloro adduct if the starting dichloropyrimidine carries excess reactive chlorine. These are disclosed in the certificate of analysis with relative retention times and response factors. The compound is stable for 36 months when stored in a desiccator over silica gel at 2–8 °C, protected from light; exposure to relative humidity above 60% for extended periods can promote 0.2–0.3% hydrolysis of the chloropyrimidine moiety to the corresponding hydroxypyrimidine derivative, which co-elutes with Impurity D in many EP methods unless a phenyl-hexyl stationary phase is substituted. This degradation pathway is monitored by periodic re-qualification using LC-MS.

Divergence from the parent drug and structurally related kinase inhibitor intermediates

The pharmacological inactivity of 2-(6-Chloro-2-Methylpyrimidin-4-Ylamino)-N-(2-Chloro-6-Methylphenyl)Thiazole-5-Carboxamide as a kinase inhibitor stems from the absence of the 4-(2-hydroxyethyl)piperazine group, which in dasatinib forms a critical hydrogen bond with the gatekeeper residue Thr315 of ABL1 kinase. In vitro kinase profiling against a panel of 50 kinases at 1 µM revealed <10% inhibition for all targets tested, confirming its suitability as a pharmacologically silent impurity standard. This contrasts sharply with the des-hydroxyethyl piperazine impurity (Impurity C), which retains moderate ABL inhibition (IC₅₀ ~200 nM) and must be controlled below 0.10% to avoid bioactivity carryover. Furthermore, unlike the N-oxide metabolite of dasatinib, this chloro intermediate does not absorb significantly at 320 nm, simplifying UV-based purity methods. Another differentiation point is the compound’s application as a versatile building block in the synthesis of kinase inhibitor libraries: the 6-chloro substituent can be exploited for late-stage diversification via Buchwald-Hartwig amination or Suzuki coupling, yielding analogues with divergent selectivity profiles. In such chemistry, the controlled presence of the 2-chloro-6-methylphenyl amide motif provides a handle for structure-activity relationship (SAR) studies at the kinase hinge region. Published synthetic procedures report that displacement of the 6-chloro substituent with piperazines proceeds in yields of 70–85% in N-methyl-2-pyrrolidone at 120 °C, catalyzed by potassium carbonate; the product of this reaction is dasatinib. Therefore, the intact chloro intermediate also serves as a critical starting material for the preparation of isotopically labelled dasatinib for bioanalytical applications, where a stable-isotope internal standard (e.g., ¹³C₂, ¹⁵N-thiazole variant) is required. In contrast, the equivalent bromo or iodo analogues display higher reactivity but increased lability during storage, leading to more pronounced impurity growth and making the chloro compound the preferred format for validated reference materials.

Differentiation from simple 2-aminothiazole carboxamides lacking the pyrimidine ring is unambiguous: the characteristic UV spectrum (λ_max 268 nm with a shoulder at 298 nm in acetonitrile/water 50:50) provides a spectral fingerprint not observed in the pyrimidine-free thiazole class. This UV signature, along with the monoisotopic mass of [M+H]⁺ 395.0132, underpins the unambiguous identification required for compendial compliance. When this compound is employed as a surrogate in method development for unknown impurities, chromatographers must be aware that its slightly higher log P (calculated 3.8 vs. 3.2 for dasatinib) translates to a distinct retention behavior on reversed-phase columns: on a biphenyl column, the elution order may invert relative to dasatinib under strongly aqueous starting conditions, a nuance documented in column vendor application notes. Published data for this specific configuration in the context of HILIC separations is limited; initial experiments suggest that the chloro impurity exhibits minimal retention on bare silica HILIC phases, making it unsuitable for orthogonal mode screening without derivatisation.

In the context of chemical procurement, distinction must also be made between this compound and its positional isomer 2-(4-chloro-6-methylpyrimidin-2-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide. The isomer, which can form if unsymmetrical 2,4-dichloro-6-methylpyrimidine is incorrectly assigned in the starting material, co-elutes with the target chloro impurity on octadecylsilane columns but can be resolved on a pentafluorophenylpropyl column (PFP) operated with a methanol-based gradient. Certified reference lots are routinely tested by 500 MHz ¹H NMR to confirm the presence of the diagnostic downfield shift of the pyrimidine C5 proton that distinguishes the 4-amino from the 2-amino regioisomer. This authentication step prevents misidentification in regulatory dossiers.

An intermediate in preclinical kinase drug discovery workflows

Despite its primary identity as a dasatinib process impurity, the compound finds substantial use as a synthetic gateway in medicinal chemistry programs targeting BCR-ABL and SRC family kinases. When the 6-chloro substituent is displaced by amines other than 2-(piperazin-1-yl)ethanol, a library of thiazole carboxamide analogues with systematically varied hinge-binding motifs is generated. In such campaigns, the compound is characterized by reaction monitoring via LCMS (single quadrupole), with the product ion at m/z 395.0 [M+H]⁺ confirming the starting material before coupling. Chemists report that residual palladium from the preparation of the compound (if made via a Suzuki route) can deactivate the catalyst in subsequent Buchwald-Hartwig steps; thus, specification sheets for synthetic-grade material include a palladium limit of <10 ppm by ICP-MS, aligned with the Ph. Eur. general monograph on heavy metals. The difference between synthetic and analytical-grade lots lies primarily in the tolerated level of residual 2-chloro-6-methylaniline, which imparts genotoxic potential and is controlled to <0.1% in reference standards but may be 0.5% in technical-grade chemical intermediates without a mutagenic impurity purge rationale. When scaling reactions beyond 10 gram batches, process chemists note that the exotherm during amide bond formation (using HOBt/EDC in DMF) requires controlled addition rates and jacket cooling to maintain the internal temperature below 5 °C to minimise dimerisation by-products, an observation derived from laboratory-scale reactor data.